Stockscreener 앱 받기
11.94
0.50%
-0.06
시간 외 거래:
11.93
-0.010
-0.08%
전일 마감가:
$12.00
열려 있는:
$12.05
하루 거래량:
66,681
Relative Volume:
0.30
시가총액:
$945.61M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+8.94%
1개월 성능:
+3.11%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$11.79
$12.35
1주일 범위
$10.82
$12.35
52주 변동 폭
$8.70
$13.18
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
명칭
Bridgebio Oncology Therapeutics Inc
전화
857 702 0377
주소
C/O CORMORANT ASSET MANAGEMENT, LP, BOSTON
BBOT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
11.94 | 950.36M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-09-15 | 개시 | H.C. Wainwright | Buy |
| 2025-08-15 | 개시 | Piper Sandler | Overweight |
Bridgebio Oncology Therapeutics Inc 주식(BBOT)의 최신 뉴스
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) - The Manila Times
BridgeBio Oncology Therapeutics, Inc. (BBOT) stock price, news, quote and history - Yahoo! Finance UK
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducin - The Manila Times
Preclinical Data Presented at the 2025 AACR-NCI-EORTC - GlobeNewswire
BBOT presents preclinical data on KRAS inhibitor BBO-11818 - BioWorld MedTech
BridgeBio Oncology announces new preclinical data on BBO-11818 study - TipRanks
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
BBOT Presents Preclinical Data Demonstrating Potential of - GlobeNewswire
BridgeBio Oncology (NASDAQ: BBOT) reports BBO-11818 panKRAS data; Phase 1, H2 2026 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), OnKure Therapeutics (OKUR) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
BridgeBio Oncology Therapeutics, Inc. (BBOT) - Yahoo! Finance Canada
BridgeBio affiliate reports 784,720 BBOT shares via services - Stock Titan
Analysts Offer Insights on Healthcare Companies: Bicara Therapeutics Inc. (BCAX) and HUTCHMED (HCM) - The Globe and Mail
Bbot announces poster presentations at the 2025 AACR-NCI-EORTC International Conference - MarketScreener
Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference - TradingView
BBOT Announces Poster Presentations at the 2025 - GlobeNewswire
2 Poster Presentations: BBOT to Present KRAS-targeted preclinical data at AACR-NCI-EORTC Oct 2025 - Stock Titan
BridgeBio Oncology Therapeutics, Inc. (BBOT) environment, social and governance (ESG) ratings - Yahoo
BridgeBio Oncology Therapeutics Rings the Closing Bell - Nasdaq
BridgeBio Oncology Therapeutics Inc (NASDAQ: BBOT) Is Up 8.01% – Is It Capable Of A Rally? - stocksregister.com
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform (BBOT:NASDAQ) - Seeking Alpha
Leerink Partners Initiates BridgeBio Oncology Therapeutics at Outperform - MarketScreener
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating - Investing.com India
H.C. Wainwright initiates BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com UK
HC Wainwright Initiates BridgeBio Oncology Therapeutics at Buy With $27 Price Target - MarketScreener
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com India
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer By Investing.com - Investing.com Nigeria
Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target - MarketScreener
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - MSN
BridgeBio Oncology Therapeutics, Inc. (BBOT) company profile and facts - Yahoo! Finance UK
BridgeBio Oncology Therapeutics shares rise 4.57% after-hours after announcing participation in September investor conferences. - AInvest
BBOT to Participate in Upcoming September Investor Healthcare Conferences - The Manila Times
BBOT to Participate in Upcoming September Investor Healthcare Conferences - GlobeNewswire Inc.
BridgeBio's Strategy To Unleash The Full Potential Of RASDrugging The Undruggable - RTTNews
BridgeBio Oncology Therapeutics shares rise 11.34% premarket after Wedbush initiates coverage. - AInvest
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
We're Hopeful That BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Will Use Its Cash Wisely - Yahoo Finance
We Think BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Can Afford To Drive Business Growth - simplywall.st
BridgeBio Oncology Therapeutics shares rise 1.17% intraday after Piper Sandler initiates coverage. - AInvest
Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target - MarketScreener
BBOT Forecast — Price Target — Prediction for 2026 - TradingView
BridgeBio Oncology initiated with an Overweight at Piper Sandler - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock Price, News, Quote & History - Yahoo! Finance Canada
What is the current Price Target and Forecast for BridgeBio Oncology Therapeutics, Inc (BBOT) - Zacks Investment Research
Bridgebio Oncology Therapeutics, Inc. shares rise 2.12% intraday after Helix Acquisition Corp. II retains more than 60% of trust account. - AInvest
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Australia
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating - Investing.com
Bridgebio Oncology Therapeutics Inc (BBOT) 재무 분석
Bridgebio Oncology Therapeutics Inc (BBOT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):